Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS.

ABSTRACT:

Background

In multiple sclerosis (MS), thalamic integrity is affected directly by demyelination and neuronal loss, and indirectly by gray/white matter lesions outside the thalamus, altering thalamic neuronal projections.

Objective

To assess the efficacy of ocrelizumab compared with interferon beta-1a (IFNβ1a)/placebo on thalamic volume loss and the effect of switching to ocrelizumab on volume change in the Phase III trials in relapsing MS (RMS, OPERA I/II; NCT01247324/NCT01412333) and in primary progressive MS (PPMS, ORATORIO; NCT01194570).

Methods

Thalamic volume change was computed using paired Jacobian integration and analyzed using an adjusted mixed-effects repeated measurement model.

Results

Over the double-blind period, ocrelizumab treatment significantly

SUBMITTER: Arnold DL 

PROVIDER: S-EPMC9493406 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature